Hayashi and colleagues26, 27 demonstrated that targeting downstream MAPK signaling with MEK inhibition in vitro was significantly more potent in NSCLC cells with RASA1/NF1 co‐mutations than a single mutation of either RASA1 gene or NF1 gene. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.